2024
Successful management of pre-existing psoriatic arthritis through targeting the IL-23/IL-17 axis in cancer patients receiving immune checkpoint inhibitor therapy: a case series
Li Y, Msaouel P, Campbell M, Hwu P, Diab A, Kim S. Successful management of pre-existing psoriatic arthritis through targeting the IL-23/IL-17 axis in cancer patients receiving immune checkpoint inhibitor therapy: a case series. RMD Open 2024, 10: e004308. PMID: 39214611, PMCID: PMC11367333, DOI: 10.1136/rmdopen-2024-004308.Peer-Reviewed Original ResearchConceptsImmune checkpoint inhibitorsImmune checkpoint inhibitor therapyAnti-IL-17A antibodyAdverse eventsAnti-PD-1 antibody monotherapyInterleukin (IL)-17/IL-23 axisPsoriatic arthritisImmune checkpoint inhibitor treatmentPD-1 antibody therapyResponse to ICI therapyImmune-related adverse eventsIL-23/IL-17 axisImmune checkpoint inhibitor exposureIL-17/23 axisAnti-CTLA-4Checkpoint inhibitor therapyCell renal cell carcinomaAnti-IL-17AAnti-IL-23 antibodyAssociated with adverse eventsPre-existing psoriasisAnti-tumor efficacyIL-23/IL-17Renal cell carcinomaICI therapy
2023
Pneumonitis After Concurrent Chemoradiation and Immune Checkpoint Inhibition in Patients with Locally Advanced Non-small Cell Lung Cancer
Altan M, Soto F, Xu T, Wilson N, Franco-Vega M, Clavijo C, Shannon V, Faiz S, Gandhi S, Lin S, Lopez P, Zhong L, Akhmedzhanov F, Godoy M, Shroff G, Wu J, Khawaja F, Kim S, Naing A, Heymach J, Daniel-Macdougall C, Liao Z, Sheshadri A. Pneumonitis After Concurrent Chemoradiation and Immune Checkpoint Inhibition in Patients with Locally Advanced Non-small Cell Lung Cancer. Clinical Oncology 2023, 35: 630-639. PMID: 37507279, DOI: 10.1016/j.clon.2023.07.003.Peer-Reviewed Original ResearchConceptsLocally advanced non-small cell lung cancerAdvanced non-small cell lung cancerNon-small cell lung cancerImmune checkpoint inhibitionLA-NSCLCCell lung cancerInterstitial lung diseaseCheckpoint inhibitionLung cancerLung diseaseRisk factorsMultivariate Cox proportional hazards modelAssociated with higher all-cause mortalityLA-NSCLC patientsMean radiation doseHazards modelMultivariable cause-specific hazards modelRetrospective chart reviewCox proportional hazards modelsAll-cause mortalityProportional hazards modelCombined chemoradiationConcurrent chemoradiationMedian ageCause-specific hazard model
2021
Newly developed pseudogout arthritis after therapy with MAGE-A4 directed TCR T cells responded to treatment with tocilizumab
Kim S, Tayar J, Fu S, Ke D, Norry E, Sun A, Miller J, Hong D. Newly developed pseudogout arthritis after therapy with MAGE-A4 directed TCR T cells responded to treatment with tocilizumab. Journal For ImmunoTherapy Of Cancer 2021, 9: e002716. PMID: 34233963, PMCID: PMC8264871, DOI: 10.1136/jitc-2021-002716.Peer-Reviewed Original ResearchConceptsImmune effector cell-associated neurotoxicity syndromeCytokine release syndromeT cellsCell therapyT-cell receptor T cellsTreatment of cytokine release syndromeImmune effector cell therapiesCalcium pyrophosphate dihydrate crystalsFallopian tube cancerT-cell therapyCD4<sup>+</sup> TDeposition of calcium pyrophosphate dihydrate crystalsTCR-T cellsEffector cell therapiesAmount of IL-6Left knee arthritisPresence of calcium pyrophosphate dihydrate crystalsMAGE-A4Th17 cellsNeurotoxicity syndromeCancer responseInterleukin-17IL-6TherapyInflammatory arthritisUse of immune checkpoint inhibitors in cancer patients with pre-existing sarcoidosis
Kim S, Pundole X, Dadu R, Lambotte O, Ramos-Casals M, Suarez-Almazor M. Use of immune checkpoint inhibitors in cancer patients with pre-existing sarcoidosis. Immunotherapy 2021, 13: 465-475. PMID: 33641345, PMCID: PMC7983044, DOI: 10.2217/imt-2020-0272.Peer-Reviewed Original ResearchConceptsImmune checkpoint inhibitorsHistory of sarcoidosisPre-existing sarcoidosisCancer patientsCheckpoint inhibitorsRemote historyDose of atezolizumabEvaluate adverse eventsFrequency of flaresICI initiationHilar lymphadenopathySymptomatic exacerbationAdverse eventsSarcoidosisSubcutaneous nodulesPatientsFluctuating courseAtezolizumabCancerInhibitorsUveitisPrednisoneLymphadenopathyExacerbationDoseDistinct Immunophenotypes of T Cells in Bronchoalveolar Lavage Fluid From Leukemia Patients With Immune Checkpoint Inhibitors-Related Pulmonary Complications
Kim ST, Sheshadri A, Shannon V, Kontoyiannis DP, Kantarjian H, Garcia-Manero G, Ravandi F, Im JS, Boddu P, Bashoura L, Balachandran DD, Evans SE, Faiz S, Vazquez W, Divenko M, Mathur R, Tippen SP, Gumbs C, Neelapu SS, Naing A, Wang L, Diab A, Futreal A, Nurieva R, Daver N. Distinct Immunophenotypes of T Cells in Bronchoalveolar Lavage Fluid From Leukemia Patients With Immune Checkpoint Inhibitors-Related Pulmonary Complications. Frontiers In Immunology 2021, 11: 590494. PMID: 33552049, PMCID: PMC7859512, DOI: 10.3389/fimmu.2020.590494.Peer-Reviewed Original ResearchConceptsImmune checkpoint inhibitorsAML/MDS patientsPulmonary complicationsAcute myeloid leukemiaMDS patientsICI groupCheckpoint inhibitorsBronchoalveolar lavageMyelodysplastic syndromeT cellsTh17/Th1 cellsBAL T cellsRisk of pneumonitisBronchoalveolar lavage fluidFungal pneumoniaPulmonary symptomsIL-17Lavage fluidPeripheral bloodTh1 cellsLeukemia patientsMyeloid leukemiaDistinct immunophenotypePatientsComplications
2019
Ex Vivo Interferon Gamma Production by Peripheral Immune Cells Predicts Survival in Lung Adenocarcinoma
Ahn S, Kwon M, Sung M, Jung S, Lee S, Park Y, Kim S, Song J. Ex Vivo Interferon Gamma Production by Peripheral Immune Cells Predicts Survival in Lung Adenocarcinoma. Clinical Lung Cancer 2019, 20: e299-e308. PMID: 30824332, DOI: 10.1016/j.cllc.2019.01.002.Peer-Reviewed Original ResearchConceptsIFN-g productionEastern Cooperative Oncology Group performance statusIFN-gLung adenocarcinomaOverall survivalPerformance statusLung cancerAssociated with lung cancer pathogenesisCancer stageProduction of IFN-gReceiver operating characteristic curve analysisStage IV lung cancerCox proportional hazards analysisTreatment-naive patientsAntitumor immune surveillanceOperating characteristics curve analysisOptimal cutoff valueOverall patient survivalInterferon-gamma productionCharacteristic curve analysisIFN-g levelsIV lung cancerProportional hazards analysisStage IV cancerLung cancer pathogenesis
2017
Successful treatment of arthritis induced by checkpoint inhibitors with tocilizumab: a case series
Kim S, Tayar J, Trinh V, Suarez-Almazor M, Garcia S, Hwu P, Johnson D, Uemura M, Diab A. Successful treatment of arthritis induced by checkpoint inhibitors with tocilizumab: a case series. Annals Of The Rheumatic Diseases 2017, 76: 2061. PMID: 28830882, DOI: 10.1136/annrheumdis-2017-211560.Peer-Reviewed Original ResearchConceptsImmune-related adverse eventsImmune checkpoint inhibitorsCheckpoint inhibitorsReceptor antibodiesAssociated with immune-related adverse eventsMild immune-related adverse eventsEffective alternative to corticosteroidsEfficacy of ICI therapyICI-induced inflammatory arthritisImmune checkpoint inhibitor therapyAnti-IL-6 receptor antibodyAlternative to corticosteroidsTreated with corticosteroidsTreated with tocilizumabTumor necrosis factor-aImmune dampening effectsInflammatory side effectsAlternative therapeutic strategiesFood and Drug AdministrationTreatment of rheumatoid arthritisJuvenile idiopathic arthritisAntitumour responseICI therapyTNFa inhibitorsCheckpoint inhibition